Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

EvoGenix completes $A5 million capital raising

EvoGenix completes $A5 million capital raising


Antibody therapeutics company EvoGenix Limited (ASX:EGX) today announced the successful completion of a $A5 million capital raising through a share placement to institutional and sophisticated investors.

The share placement is for 10 million shares at an issue price of $0.50 per share.

The placement included investments both from existing shareholders and from a number of other institutional investors with expertise in the biotechnology sector.

EvoGenix CEO and Managing Director Merilyn Sleigh commented that the additional capital will be used primarily to accelerate development of the company’s product pipeline with particular emphasis on anti-cancer antibody drugs under development.

Dr Sleigh noted “EvoGenix has been able to access two very exciting prospects for novel cancer treatments through agreements announced this year with the University of Massachusetts, USA and the US National Institutes of Health. These offer new approaches to treatment of cancers where an effective drug could be expected to achieve more than a billion dollars in annual sales. Our work during the next 12 months will be focused on confirming the effectiveness of these potential treatments in our pre-clinical studies, accelerating products through to the clinical testing phase.”

Lodge Corporate Services Pty Ltd acted as Adviser and Lead Manager for the placement.

Details of the raising

EvoGenix will issue 10 million new shares as a result of the placement. This represents less than 15% of the company’s total issued capital, allowing the issue to proceed under Rule 7.1 of the ASX listing rules without additional shareholder approval. Application for listing of the new shares will be made in the near future.

About EvoGenix

EvoGenix Limited (ASX:EGX) has established leading technology capabilities for creating high value antibody and protein-based therapeutics. The company exploits its capabilities through technology collaborations with partner companies, and by development in-house of a succession of wholly-owned antibody and protein products.

Antibodies are natural proteins designed to attack, block and remove unwanted materials
from the body. Antibodies are usually first made in animals such as mice or rats, and in their initial state are unsuitable for use in patients, because the foreign protein is rapidly rejected by the human immune system.

The EvoGenix technology can convert a research-stage antibody into a high potency therapeutic suitable for long term administration to patients. This is a key value-creating step in antibody development.

EvoGenix is progressively building company value by assembling a portfolio of revenues from technology collaborations using its unique technology capabilities. Multi project collaborations with GlaxoSmithKline and Australia’s CSL Limited have been announced in the past 12 months.

At the same time EvoGenix is advancing its internal product pipeline, with current products aimed at the treatment of osteoporosis, lung cancer, melanoma and respiratory infections. Generally, these will be out-licensed prior to the clinical stage to meet the existing high demand for new biotherapeutic products in the pharmaceutical industry.

Ends

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Government: New Year Border Exception For Seasonal Workers In The Horticulture And Wine Industries

2000 additional RSE workers to enter New Zealand early next year employers must pay these workers at least $22.10 an hour employers will cover costs of managed isolation for the RSE workers RSE workers will be paid the equivalent of 30 hours work a week ... More>>

ALSO:

Grey Power: Is Disappointed To Learn Of More Bank Closures

Many older people are being left without essential services because of cost cutting and the march of modern technology. It is now expected that most banking transactions can occur via the internet or telephone. Jan Pentecost, President of the Grey Power ... More>>

ALSO:

Economy: Supply Chain On Brink Of Overload Says National Road Carriers

The New Zealand supply chain is on the brink of overload and it looks like the upcoming peak imports season may push it over the edge says National Road Carriers Association (NRC) CEO David Aitken. “Worldwide supply chains are in disarray,” says Mr Aitken. ... More>>

Stats NZ: Annual Goods Trade Surplus At 28-Year High

New Zealand’s annual goods trade surplus reached a 28-year high of $2.2 billion as imports tumbled in the year ended October 2020, Stats NZ said today. “This is the largest annual surplus since the July 1992 year, driven mainly by much lower ... More>>

ComCom: How Real Is That Bargain?

The Commerce Commission urges retailers and consumers to think hard about the bargains being offered as ‘Black Friday’ and Christmas draw near. Black Friday has now overtaken Boxing Day in terms of retail spending, according to data from electronic ... More>>

Stats NZ: Births And Deaths: Year Ended September 2020

Births and deaths releases provide statistics on the number of births and deaths registered in New Zealand, and selected fertility and mortality rates. Key facts For the year ended September 2020: 57,753 live births and 32,670 deaths ... More>>

ALSO:


Forest & Bird: Kākāpō Wins Bird Of The Year 2020

The nation has voted and Aotearoa New Zealand has a new Bird of the Year. New Zealand’s moss-colored flightless parrot has climbed to the top-spot for the second time in Forest & Bird’s annual Te Manu Rongonui o Te Tau/Bird of the Year competition. ... More>>